DermaFlow has developed a non-invasive proprietary and patented technology that accurately and cost effectively measures directly peripheral (in the capillaries) blood flow and detects tell-tale changes in microcirculation. It has been estimated that ~ 90% of disease results in microcirculation changes, and therefore having a "friendly" and affordable way to monitor this routinely is of significant value to modern healthcare. This technology lends itself easily and expediently to three major healthcare trends: *stream-lined 510 K predicate regulatory track designated (for a stand-alone device) * wireless monitoring for home and remote situations * integration into existing monitoring and/or sensing devices DermaFlow has completed early proof-of-concept clinical studies, and is focusing currently on acute care (sepsis in ICU patients) with its first stand alone product Perichek Multi. In addition, Dermaflow has completed development of Perichek - a module suitable for integration into established patient monitoring suites. Dermaflow technology has a wide range of applications in acute and chronic care, both in and out of hospital. We welcome interested corporate, clinical, and strategic partners as well as accredited investors.